Answers are grounded in this paper and cite their sources.
The use of vaccines in the prevention of meningococcal disease has demonstrated their success in improving public health globally. Group C conjugate vaccines have significantly reduced the burden of disease in countries with widespread usage. Promising results are available on the candidate group A conjugate vaccine for Africa, which could potentially control the epidemics observed in the meningitis belt at a cost that is affordable. For group B, promising candidate antigens have been identified and are currently in Phase II clinical trials. The prospect of a vaccine against group B is now realistic, with potential licensure submission within the foreseeable future.
No takes yet. Share an insight, caveat, or question.
Borrow et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: